The stock of Novavax, Inc. (NVAX) has seen a -4.66% decrease in the past week, with a -14.36% drop in the past month, and a -6.92% decrease in the past quarter. The volatility ratio for the week is 5.48%, and the volatility levels for the past 30 days are at 8.19% for NVAX. The simple moving average for the last 20 days is -8.84% for NVAX stock, with a simple moving average of -26.26% for the last 200 days.
Is It Worth Investing in Novavax, Inc. (NASDAQ: NVAX) Right Now?
The 36-month beta value for NVAX is at 1.59. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NVAX is 131.81M, and currently, shorts hold a 40.01% of that float. The average trading volume for NVAX on March 27, 2024 was 8.74M shares.
NVAX) stock’s latest price update
Novavax, Inc. (NASDAQ: NVAX)’s stock price has decreased by -2.08 compared to its previous closing price of 4.81. However, the company has seen a -4.66% decrease in its stock price over the last five trading sessions. 24/7 Wall Street reported 2024-03-15 that Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with B. Riley Securities repeating the rating for NVAX by listing it as a “Buy.” The predicted price for NVAX in the upcoming period, according to B. Riley Securities is $15 based on the research report published on August 09, 2023 of the previous year 2023.
TD Cowen, on the other hand, stated in their research note that they expect to see NVAX reach a price target of $10, previously predicting the price at $55. The rating they have provided for NVAX stocks is “Market Perform” according to the report published on April 20th, 2023.
B. Riley Securities gave a rating of “Neutral” to NVAX, setting the target price at $10 in the report published on March 01st of the previous year.
NVAX Trading at 2.78% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.54% of loss for the given period.
Volatility was left at 8.19%, however, over the last 30 days, the volatility rate increased by 5.48%, as shares sank -21.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.84% upper at present.
During the last 5 trading sessions, NVAX fell by -4.66%, which changed the moving average for the period of 200-days by -38.75% in comparison to the 20-day moving average, which settled at $5.10. In addition, Novavax, Inc. saw -1.88% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -0.69 for the present operating margin
- 0.59 for the gross margin
The net margin for Novavax, Inc. stands at -0.67. The total capital return value is set at -2.57.
Based on Novavax, Inc. (NVAX), the company’s capital structure generated -0.38 points at debt to capital in total, while cash flow to debt ratio is standing at -3.64. The debt to equity ratio resting at -0.27. The interest coverage ratio of the stock is -39.3.
Currently, EBITDA for the company is -373.8 million with net debt to EBITDA at 0.6. When we switch over and look at the enterprise to sales, we see a ratio of 0.44. The receivables turnover for the company is 2.75for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.70.
Conclusion
In conclusion, Novavax, Inc. (NVAX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
